SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-22-145709
Filing Date
2022-05-10
Accepted
2022-05-10 07:46:20
Documents
55
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d347388d10q.htm   iXBRL 10-Q 836566
2 EX-10.1 d347388dex101.htm EX-10.1 18422
3 EX-31.1 d347388dex311.htm EX-31.1 6442
4 EX-31.2 d347388dex312.htm EX-31.2 6284
5 EX-32 d347388dex32.htm EX-32 4342
  Complete submission text file 0001193125-22-145709.txt   4006967

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA itci-20220331.xsd EX-101.SCH 29365
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE itci-20220331_cal.xml EX-101.CAL 32892
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE itci-20220331_def.xml EX-101.DEF 173335
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20220331_lab.xml EX-101.LAB 297378
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20220331_pre.xml EX-101.PRE 253288
49 EXTRACTED XBRL INSTANCE DOCUMENT d347388d10q_htm.xml XML 534924
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36274 | Film No.: 22907403
SIC: 2834 Pharmaceutical Preparations